Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

APRE

Aprea Therapeutics Inc

Last Close
Sep 20 • 04:00PM ET
3.13
Dollar change
+0.21
Percentage change
7.19 		%
Held by: VTI VXF DFAT DFAC
Index- P/E- EPS (ttm)-3.03 Insider Own11.32% Shs Outstand5.43M Perf Week-0.64%
Market Cap17.00M Forward P/E- EPS next Y-1.54 Insider Trans0.00% Shs Float4.82M Perf Month-18.91%
Income-12.93M PEG- EPS next Q-0.72 Inst Own38.37% Short Float0.23% Perf Quarter-21.95%
Sales1.28M P/S13.28 EPS this Y30.55% Inst Trans-47.36% Short Ratio1.23 Perf Half Y-50.71%
Book/sh4.71 P/B0.66 EPS next Y44.01% ROA-44.09% Short Interest0.01M Perf Year-23.84%
Cash/sh5.28 P/C0.59 EPS next 5Y- ROE-50.11% 52W Range2.86 - 8.85 Perf YTD-33.40%
Dividend Est.- P/FCF- EPS past 5Y23.41% ROI-48.11% 52W High-64.62% Beta1.04
Dividend TTM- Quick Ratio9.55 Sales past 5Y0.00% Gross Margin- 52W Low9.44% ATR (14)0.23
Dividend Ex-Date- Current Ratio9.55 EPS Y/Y TTM86.77% Oper. Margin-1112.69% RSI (14)43.41 Volatility6.32% 6.48%
Employees7 Debt/Eq0.00 Sales Y/Y TTM410.91% Profit Margin-1013.41% Recom1.00 Target Price15.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q33.09% Payout- Rel Volume2.49 Prev Close2.92
Sales Surprise1023.20% EPS Surprise5.89% Sales Q/Q124.91% EarningsAug 12 BMO Avg Volume8.96K Price3.13
SMA20-5.67% SMA50-12.23% SMA200-36.28% Trades Volume22,267 Change7.19%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20Initiated Berenberg Buy $37
Sep-29-20Resumed JP Morgan Neutral $25
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Today 08:35AM
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
(GlobeNewswire) +7.19%
Sep-16-24 12:07PM
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
(GlobeNewswire)
Sep-12-24 08:30AM
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
(GlobeNewswire) +6.21%
Sep-09-24 05:15PM
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire)
04:05PM
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire)
08:30AM Loading…
Aug-28-24 08:30AM
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire)
Aug-12-24 09:45AM
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
08:30AM
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire)
Jul-17-24 08:00AM
Alltrna Announces Updates to Its Board of Directors
(PR Newswire)
Jun-21-24 08:00AM
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
(GlobeNewswire)
Jun-17-24 08:30AM
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
(GlobeNewswire)
May-28-24 08:45AM
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
(GlobeNewswire)
May-14-24 01:53PM
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
(InvestorPlace) +5.37%
08:30AM
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
(GlobeNewswire)
May-13-24 04:01PM
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
09:15AM Loading…
May-02-24 09:15AM
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-10-24 12:00PM
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
(GlobeNewswire)
Mar-26-24 01:53PM
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
07:45AM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Mar-11-24 08:30AM
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
(GlobeNewswire) -5.05%
08:29AM
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
(GlobeNewswire)
Mar-05-24 04:45PM
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
(GlobeNewswire)
Feb-06-24 08:01AM
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
(GlobeNewswire) +11.97%
Jan-30-24 08:00AM
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
(GlobeNewswire)
Jan-04-24 04:05PM
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
(GlobeNewswire)
Nov-09-23 04:05PM
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire) -5.19%
Oct-24-23 08:00AM
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
(GlobeNewswire)
Oct-16-23 08:30AM
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
(GlobeNewswire)
Sep-19-23 08:00AM
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-11-23 08:00AM
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
(GlobeNewswire)
04:05PM Loading…
Sep-06-23 04:05PM
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-24-23 07:30AM
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
(GlobeNewswire)
Aug-10-23 07:30AM
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Jun-14-23 08:00AM
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
(GlobeNewswire)
May-30-23 08:30AM
Aprea Therapeutics to Present at BIO International Convention
(GlobeNewswire) +11.76%
May-15-23 04:05PM
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
(GlobeNewswire)
Apr-24-23 09:55AM
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
(Zacks)
Apr-04-23 12:00PM
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
(Zacks) -5.01%
Mar-30-23 04:05PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Mar-16-23 08:00AM
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
(GlobeNewswire)
Mar-07-23 08:00AM
Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference
(GlobeNewswire) -5.26%
Mar-01-23 04:05PM
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Feb-27-23 04:05PM
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire)
Feb-22-23 08:41PM
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire) -19.97%
04:05PM
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
(GlobeNewswire)
Feb-15-23 08:00AM
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
(GlobeNewswire)
Feb-13-23 07:00AM
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
(GlobeNewswire)
Jan-30-23 08:00AM
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
(GlobeNewswire)
Jan-19-23 08:00AM
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
(GlobeNewswire) -7.57%
Jan-12-23 09:56AM
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
(Zacks)
Jan-11-23 08:00AM
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
(GlobeNewswire) +11.99%
Nov-09-22 04:15PM
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -10.88%
Sep-22-22 06:00PM
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
(GlobeNewswire) -7.14%
Sep-08-22 08:00AM
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
(GlobeNewswire)
Aug-11-22 04:15PM
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Aug-02-22 08:00AM
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
(GlobeNewswire)
May-19-22 06:30AM
The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal
(American City Business Journals)
May-16-22 09:21AM
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
(GlobeNewswire) -19.09%
Mar-15-22 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire) +5.45% +14.37%
Mar-02-22 04:41AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?
(Simply Wall St.)
Jan-14-22 10:00AM
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-06-22 08:00AM
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
(GlobeNewswire)
Dec-14-21 08:00AM
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.05%
Dec-13-21 08:00AM
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.85%
Dec-10-21 10:30AM
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
(Zacks)
Dec-09-21 12:30PM
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
(Benzinga)
08:00AM
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
(GlobeNewswire)
Nov-08-21 04:15PM
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Nov-04-21 04:15PM
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
(GlobeNewswire)
Sep-21-21 08:39AM
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
(Benzinga)
07:01AM
18 Stocks Moving in Tuesday's Pre-Market Session
(Benzinga)
Sep-20-21 04:15PM
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
08:42AM
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
(Zacks)
Sep-14-21 08:00AM
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
Sep-03-21 07:21AM
Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares?
(Simply Wall St.)
Aug-12-21 04:15PM
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -9.65%
06:00AM
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
(GlobeNewswire)
Aug-05-21 05:00PM
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
(GlobeNewswire)
Jul-21-21 08:00AM
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
(GlobeNewswire) -5.52%
Jun-18-21 08:34AM
Implied Volatility Surging for Aprea (APRE) Stock Options
(Zacks)
Jun-17-21 09:19AM
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
(Zacks) -6.32%
Jun-16-21 09:24AM
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
(Benzinga) +10.93%
08:00AM
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
(GlobeNewswire)
Jun-13-21 12:45PM
Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?
(Insider Monkey)
Jun-04-21 01:47AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?
(Simply Wall St.)
May-21-21 06:00AM
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
(GlobeNewswire)
May-18-21 06:00AM
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-06-21 04:15PM
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Apr-16-21 09:15AM
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
(GlobeNewswire) +7.64%
Apr-08-21 11:15AM
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
(GlobeNewswire) +13.64%
Mar-16-21 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Feb-16-21 08:04AM
Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?
(Simply Wall St.)
Jan-22-21 12:00PM
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
(Zacks)
Jan-08-21 08:00AM
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
(GlobeNewswire)
Dec-30-20 11:40AM
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
(Zacks)
Dec-29-20 07:24PM
Dont Go Bargain Hunting on Aprea Stock, Says Analyst
(TipRanks) -8.18%
10:32AM
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
(Zacks)
Dec-28-20 04:57PM
10 Biggest Stock Gainers and Losers Today
(Insider Monkey) -78.08%
02:22PM
Aprea Shares Slump After Cancer-Drug Trial Misses Key Goal
(TheStreet.com)
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrMar 13 '24Buy7.291,0107,36315,503Mar 14 08:54 PM
Seizinger Bernd R.DirectorMar 13 '24Buy7.296,86050,00933,685Mar 14 08:53 PM
HENNEMAN JOHN B IIIDirectorMar 13 '24Buy7.296,86050,0098,139Mar 14 08:52 PM
Gilad OrenPresident, CEOMar 13 '24Buy7.292,00014,580324,770Mar 14 08:51 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

WINT

Windtree Therapeutics Inc

Last Close
Sep 20 • 04:00PM ET
3.13
Dollar change
-0.11
Percentage change
-3.40 		%
WINT Windtree Therapeutics Inc daily Stock Chart
Held by: VXF
Index- P/E- EPS (ttm)-29.88 Insider Own13.38% Shs Outstand1.61M Perf Week-1.26%
Market Cap5.04M Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float1.40M Perf Month-70.30%
Income-11.38M PEG- EPS next Q-0.37 Inst Own0.09% Short Float7.53% Perf Quarter-0.32%
Sales0.00M P/S- EPS this Y97.48% Inst Trans- Short Ratio0.08 Perf Half Y-51.02%
Book/sh5.90 P/B0.53 EPS next Y10.50% ROA-32.86% Short Interest0.11M Perf Year-82.61%
Cash/sh1.12 P/C2.80 EPS next 5Y- ROE-103.25% 52W Range2.75 - 27.00 Perf YTD-75.82%
Dividend Est.- P/FCF- EPS past 5Y66.05% ROI-100.21% 52W High-88.41% Beta0.59
Dividend TTM- Quick Ratio0.23 Sales past 5Y-37.79% Gross Margin- 52W Low13.82% ATR (14)0.95
Dividend Ex-Date- Current Ratio0.23 EPS Y/Y TTM93.48% Oper. Margin0.00% RSI (14)33.25 Volatility8.05% 22.60%
Employees15 Debt/Eq0.37 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q29.07% Payout- Rel Volume0.19 Prev Close3.24
Sales Surprise- EPS Surprise-157.83% Sales Q/Q- EarningsAug 20 AMC Avg Volume1.33M Price3.13
SMA20-43.26% SMA50-54.39% SMA200-55.10% Trades Volume251,393 Change-3.40%
Date Action Analyst Rating Change Price Target Change
Jun-26-20Initiated Ladenburg Thalmann Buy $12.25
Sep-04-24 08:00AM
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Aug-20-24 04:05PM
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
(GlobeNewswire) -6.06%
Aug-14-24 04:05PM
Windtree Announces New Additions and Changes to Its Board of Directors
(GlobeNewswire) +9.11%
Jul-26-24 07:36AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace) +151.98%
Jul-25-24 08:00AM
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
(GlobeNewswire) -10.60%
04:05PM Loading…
Jul-22-24 04:05PM
Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock
(GlobeNewswire)
May-24-24 07:16AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace) +7.73%
May-07-24 08:00AM
Windtree Therapeutics Regains Compliance with Nasdaq
(GlobeNewswire) -9.74%
Apr-18-24 08:00AM
Windtree Therapeutics Announces Reverse Stock Split
(GlobeNewswire) -15.32%
Apr-17-24 08:00AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
06:52AM
WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
Apr-08-24 04:48PM
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
(GlobeNewswire) -9.51%
Feb-01-24 08:00AM
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
(GlobeNewswire)
Jan-31-24 08:00AM
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
(GlobeNewswire) -6.60%
Jan-26-24 09:20AM
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
(ACCESSWIRE)
08:30AM Loading…
Jan-25-24 08:30AM
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
(GlobeNewswire)
Jan-18-24 09:00AM
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
(ACCESSWIRE)
Jan-17-24 08:00AM
Windtree Therapeutics Announces License Agreement with Lees Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
(GlobeNewswire) -18.04%
Jan-02-24 04:05PM
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
(GlobeNewswire) -10.61%
Dec-19-23 09:30AM
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
(ACCESSWIRE)
Dec-18-23 08:00AM
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Nov-16-23 08:00AM
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
(GlobeNewswire)
Nov-14-23 08:55AM
Sidoti Events, LLCs Virtual November Micro-Cap Conference
(ACCESSWIRE)
Nov-09-23 04:15PM
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Nov-08-23 08:00AM
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
(GlobeNewswire)
Oct-12-23 07:30AM
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
(GlobeNewswire) +18.42%
Oct-10-23 07:30AM
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
(GlobeNewswire)
Oct-03-23 08:00AM
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
(GlobeNewswire)
Sep-21-23 09:35AM
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
(GlobeNewswire)
Aug-25-23 07:20AM
7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole
(InvestorPlace) -7.02%
08:00AM Loading…
Aug-23-23 08:00AM
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
(GlobeNewswire)
Aug-16-23 09:00AM
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
(ACCESSWIRE)
Aug-07-23 04:05PM
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire) +6.82%
Jul-25-23 09:25AM
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
(ACCESSWIRE)
Jul-18-23 09:00AM
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
(ACCESSWIRE)
Jul-14-23 09:00AM
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That
(ACCESSWIRE)
Jun-27-23 08:00AM
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
(GlobeNewswire)
Jun-12-23 08:00AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
(GlobeNewswire) -5.08%
Jun-05-23 08:00AM
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
(GlobeNewswire) +8.63%
May-15-23 04:30PM
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
May-11-23 12:20PM
10 Best Stocks to Buy for a Quick Return
(Insider Monkey)
Apr-27-23 08:00AM
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
(GlobeNewswire)
Apr-24-23 04:01PM
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
(GlobeNewswire) -12.26%
Apr-20-23 08:30AM
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
(GlobeNewswire) -57.68%
Apr-17-23 08:00AM
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
(GlobeNewswire) +88.81%
Apr-03-23 07:35AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Mar-13-23 08:00AM
Windtree Regains Compliance with Nasdaq
(GlobeNewswire)
Mar-06-23 08:00AM
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
(GlobeNewswire)
Feb-28-23 08:00AM
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
(GlobeNewswire)
Feb-27-23 08:00AM
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
(GlobeNewswire) -8.99%
Feb-24-23 08:00AM
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
(GlobeNewswire) -15.85%
Feb-23-23 12:00PM
Windtree Therapeutics Announces Reverse Stock Split
(GlobeNewswire) -34.40%
Jan-20-23 08:37AM
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
(GlobeNewswire) -25.65%
Dec-05-22 07:30AM
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
(GlobeNewswire) -5.43%
Nov-18-22 12:00PM
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
(Zacks)
Nov-14-22 07:30AM
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Oct-25-22 08:00AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
(GlobeNewswire)
Oct-06-22 06:50AM
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Sep-29-22 07:45AM
Windtree Therapeutics Stock Surges After Positive Istaroxime Data In Cardiogenic Shock
(Benzinga) +6.15%
Sep-28-22 04:05PM
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
(GlobeNewswire)
Sep-26-22 08:00AM
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
(GlobeNewswire)
Sep-21-22 04:05PM
Windtree to Present at the Ladenburg Thalmann Healthcare Conference
(GlobeNewswire) -6.13%
Sep-06-22 04:05PM
Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Aug-24-22 02:59PM
Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M
(American City Business Journals) -28.14%
Aug-23-22 08:00AM
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
(GlobeNewswire) +52.21%
Aug-11-22 04:05PM
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Jun-29-22 08:00AM
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
(GlobeNewswire)
May-23-22 10:12AM
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
(GlobeNewswire) -11.25%
May-16-22 07:00AM
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire) +6.82%
May-05-22 04:05PM
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire) -7.75%
Apr-20-22 04:05PM
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
(GlobeNewswire) -14.63%
07:00AM
Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Mar-31-22 04:05PM
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
(GlobeNewswire)
03:26PM
Insiders who purchased Windtree Therapeutics, Inc. (NASDAQ:WINT) stock last year recover some losses which currently stand at US$47k
(Simply Wall St.)
07:05AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Mar-22-22 01:47PM
Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress
(Benzinga)
07:30AM
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
(GlobeNewswire)
Mar-15-22 12:06PM
Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April
(Benzinga)
07:00AM
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Mar-10-22 08:00AM
Windtree to Present at Oppenheimers 32nd Annual Healthcare Conference
(GlobeNewswire)
Feb-01-22 02:36PM
Why Are Windtree Therapeutics Shares Trading Higher Today?
(Benzinga) +15.93%
07:30AM
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome
(GlobeNewswire)
Dec-15-21 08:00AM
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
(GlobeNewswire)
Nov-22-21 04:59PM
2 Moonshot Biotechs with 10x Potential
(InvestorPlace) +11.26%
08:00AM
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay Adding to Previously Reported Need for New Pharmacologic Innovation
(GlobeNewswire)
Nov-10-21 04:05PM
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Oct-26-21 10:33AM
3 Moonshot Stocks Insiders Are Buying and 2 That Are Getting Dumped
(InvestorPlace)
08:51AM
2 Penny Stocks Insiders Are Buying
(Benzinga)
Oct-25-21 07:30AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
(GlobeNewswire)
Oct-20-21 07:36AM
3 Penny Stocks Insiders Are Buying
(Benzinga) +5.79%
Oct-14-21 07:30AM
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock
(GlobeNewswire)
Oct-12-21 07:30AM
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
(GlobeNewswire)
Sep-30-21 02:25PM
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Sep-16-21 07:30AM
Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
(GlobeNewswire)
Aug-05-21 04:01PM
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire) -10.40%
Aug-02-21 08:00AM
Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
(GlobeNewswire)
Jul-08-21 11:20AM
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
(ACCESSWIRE)
07:30AM
Windtree to Present at Access to Giving Virtual Investor Conference
(GlobeNewswire)
Jul-07-21 07:30AM
Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
(GlobeNewswire)
Jul-01-21 07:30AM
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
(PR Newswire)
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOSep 27 '23Buy1.022,5002,55057,877Sep 28 07:24 AM
Fraser CraigPresident and CEOSep 26 '23Buy0.902,5002,25055,377Sep 27 07:34 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.